• Teva Pharmaceutical Industries Ltd., of Jerusalem, presented Phase III results showing that lipegfilgrastim and balugrastim, long-acting granulocyte colony-stimulating factors, achieved the primary endpoint in breast cancer studies, demonstrating reduction in the duration of severe neutropenia in cycle 1, comparable to Neulasta (pegfilgrastim, Amgen Inc.) in both efficacy and safety measures.